Circulating tumor DNA (ctDNA) mutations and circulating tumor cell (CTC) biomarkers demonstrated strong clinical concordance across localized, progressive, and metastatic cancer stages, highlighting their value in comprehensive disease monitoring.
The integration of genomic biomarkers from ctDNA and cellular biomarkers from CTCs provides a multidimensional understanding of tumor biology and disease progression.
Combined ctDNA–CTC analysis improves prognostic accuracy by capturing both tumor-derived genetic alterations and circulating tumor cell dynamics.
ctDNA profiling enables detection of tumor-specific genomic mutations and molecular evolution, while CTC analysis offers insights into tumor cell dissemination and metastatic potential.
This dual biomarker strategy supports longitudinal monitoring of cancer progression, enabling clinicians to track disease status across the entire treatment journey.
The approach enhances non-invasive cancer surveillance, reducing dependence on repeated tissue biopsies and invasive diagnostic procedures.
Integrated ctDNA–CTC liquid biopsy may facilitate earlier detection of disease progression and treatment resistance, improving clinical decision-making.
Overall, the ctDNA–CTC biomarker duo represents a powerful tool for precision oncology, real-time disease monitoring, and personalized cancer management across the disease continuum.